One-shot dalbavancin infusion combined with vacuum-assisted closure of Crohn's anal fistulas

Jacek Hermann¹ , Hanna Tomczak^{2,3} , Barbara Kołodziejczak⁴ , Dorota Mańskowska-Wierzbicka⁵ , Tomasz Banasiewicz¹ , Ryszard Marciniak¹

¹Department of General, and Endocrinologic Surgery, and Gastroenterologic Oncology, Poznań University of Medical Sciences, Poznań, Poland

²Department of Genetics and Pharmaceutical Microbiology, Poznań University of Medical Sciences, Poznań, Poland

³Central Microbiology Laboratory, Clinical Hospital at the Poznań University of Medical Sciences, Poznań, Poland

⁴Department of Computer Science and Statistics, Poznań University of Medical Sciences, Poznań, Poland

⁵Department of Gastroenterology, Human Nutrition, and Internal Medicine, Poznań University of Medical Sciences, Poznań, Poland

Cite this article as: Hermann J, Tomczak H, Kołodziejczak B, Mańskowska-Wierzbicka D, Banasiewicz T, Marciniak R. One-shot dalbavancin infusion combined with vacuum-assisted closure of Crohn's anal fistulas. *Turk J Gastroenterol* 2019; 30: 114-5.

Dear Editor,

There remains a high rate of recurrences after the treatment of Crohn's anal fistulas with abscesses (CFA), even more with the super infection of methicillin-resistant *Staphylococcus aureus* (MRSA). The patients are hospitalized on the same day either with multiple surgical interventions and the possible risk of damage to the anal sphincter or with conservative surgery in the form of incision and non-cutting drainage setons following the prolonged intravenous administration of antibiotics. That treatment delays introduction of the biological therapy. One-shot intravenous dalbavancin infusion combined with negative pressure drainage (VAC) of Crohn's anal fistulas may be an alternative to traditional methods (1,2).

Medical records of five patients with complex CFA accompanied with MRSA superinfection were retrospectively evaluated. Cultures showed MRSA sensitive to various antibiotics such as vancomycin, teicoplanin, linezolid, clindamycin, levofloxacin, ciprofloxacin, and dalbavancin. The incision of abscesses accompanying the fistulas in all the patients, curettage, and cauterization of fistulous tracts were followed with the application of VAC. A catheter wrapped with a regular polyurethane open-pored sponge was introduced into the fistulous tracts with abscess cavities and fixed to the adjacent skin with an adhesive foil. Lastly, an opening in the foil was made, and a negative pressure port was installed. During the treatment, a stable negative pressure of 100-150 mmHg was maintained. Afterwards, one-shot intravenous injection of dalbavancin was administered at 1500-mg dose. VAC was applied on average 3-4 times, every third or fourth day, and removed in

1-2 weeks if the inflammatory process receded. During each change, the size of the sponge was reduced with a shrinking abscess cavity and the catheter was gradually removed from the tract with the aim to collapse and finally close it. Infliximab administration was initiated in fortnight. The final healing time ranged from 1 to 6 months.

VAC may be an alternative to the traditional methods of treatment since any discharge is evacuated more effectively. Moreover, edema reduced, blood flow increased, wounds shrunk, and the formation of the fresh granulation tissue accelerated. VAC can also be defined as a sphincter-saving procedure since the anal sphincter is left intact (3). An extensive infection of the perianal skin accompanying CF requires the prolonged intravenous administration of antibiotics. Since the colon is the source of primary perianal infection in patients, ciprofloxacin is administered with metronidazole with good clinical result in most cases (4). However, there is a risk of super infection with MRSA in time. An alternative to comparable antibiotics against methicillin-resistant *S. aureus* administered at hospitals may be dalbavancin. It is a recently approved new-generation semisynthetic lipoglycopeptide that belongs to the same class as vancomycin and teicoplanin; however, it has a higher potency against Gram-positive bacteria. Its mechanism of action relies on the inhibition of the bacterial cell wall biosynthesis. Because it has a uniquely long elimination half-life, it can be intravenously administered in one shot at 1500-mg dose. Lastly, the penetration of dalbavancin into skin is good and long-lasting even after the above-mentioned short regimen (5).

Peer-review: Externally peer-reviewed.

Corresponding Author: Jacek Hermann; jacekhermann@gmail.com

Received: December 17, 2017 Accepted: May 10, 2018 Available online date: November 14, 2018

© Copyright 2019 by The Turkish Society of Gastroenterology · Available online at turkjgastroenterol.org

DOI: 10.5152/tjg.2018.17829

Author Contributions: Concept - J.H., T.B.; Design - H.T.; Supervision - J.H.; Resources - R.M.; Materials - D.M.; Data Collection and/or Processing - Hanna Tomczak; Analysis and/or Interpretation - J.H.; Literature Search - H.T.; Writing Manuscript - J.H.; Critical Review - R.M.

Conflict of Interest: The authors have no conflict of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

REFERENCES

1. Klag T, Goetz M, Stange EF, Wehkamp J. Medical therapy of perianal Crohn's disease. *Viszeralmedizin* 2015; 31: 265-72.
2. Hermann J, Eder P, Banasiewicz T, Matysiak K, Łykowska-Szuber L. Current management of anal fistulas in Crohn's disease. *Gastroenterology Review*. 2015; 10: 83-88.
3. Banasiewicz T, Hermann J, Krokowicz Ł, Drew M. "Sandwich technique" with bridging, a modification of negative pressure wound therapy for anal fistulas. *Tech Coloproctol* 2015; 19: 173-5. [\[CrossRef\]](#)
4. Solomon M, McLeod R, O'Connor B, Steinhart A, Greenberg G, Cohen Z. Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease. *Can J Gastroenterol*. 1993; 7: 571-3. [\[CrossRef\]](#)
5. Dunne MW, Puttagunta S, Giordano P, et al. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection. *Clin Infect Dis* 2016; 62: 545-51. [\[CrossRef\]](#)